OncoMatch/Clinical Trials/NCT06455410
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
Is NCT06455410 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including GP and Adebrelimab for nasopharyngeal carcinoma.
Treatment: GP · Adebrelimab · concurrent chemoradiotherapy (CCRT) — The purpose of this study is to explore the efficacy and safety of neoadjuvant GP chemotherapy plus adebrelimab versus neoadjuvant GP chemotherapy in treating high-risk locoregionally advanced nasopharyngeal carcinoma patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T4N0-1M0, T1-4N2-3M0 (AJCC 8th)
Tumor staged as T4N0-1M0 or T1-4N2-3M0 (AJCC 8th)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiation therapy
Prior therapy with radiation or systemic chemotherapy
Cannot have received: cytotoxic chemotherapy
Prior therapy with radiation or systemic chemotherapy
Cannot have received: immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-CTLA-4)
Prior exposure to immune checkpoint inhibitors,including anti-PD-1, anti- PD-L1, anti-CTLA-4 antibodies
Lab requirements
Blood counts
WBC ≥4.0×10^9 /L, Hemoglobin ≥ 90g/L, Platelet count ≥100×10^9/L
Kidney function
creatinine clearance rate ≥ 60 ml/min or Creatinine ≤ 1.5× upper limit of normal value
Liver function
ALT, AST, TBIL ≤2×upper limit of normal (ULN)
Adequate marrow function: White blood cell count (WBC)≥4.0×109 /L, Hemoglobin ≥ 90g/L, Platelet count ≥100×109/L. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL) ≤2×upper limit of normal (ULN). Adequate renal function: creatinine clearance rate ≥ 60 ml/min or Creatinine ≤ 1.5× upper limit of normal value.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06455410 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T4N0-1M0 or T1-4N2-3M0 is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages